<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Jpn J Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">Jpn. J. Cancer Res</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006a</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Japanese Journal of Cancer Research : Gann</journal-title></journal-title-group><issn pub-type="ppub">0910-5050</issn><issn pub-type="epub">1876-4673</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8698630</article-id><article-id pub-id-type="pmc">5921149</article-id><article-id pub-id-type="doi">10.1111/j.1349-7006.1996.tb00292.x</article-id><article-id pub-id-type="publisher-id">CAE781</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Determinants of Myelosuppression in the Treatment of Non&#x02010;small Cell Lung Cancer with Cisplatin&#x02010;containing Chemotherapy</article-title></title-group><contrib-group><contrib id="cr1" contrib-type="author"><name><surname>Matsui</surname><given-names>Kaoru</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr2" contrib-type="author" corresp="yes"><name><surname>Masuda</surname><given-names>Noriyuki</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr3" contrib-type="author"><name><surname>Uchida</surname><given-names>Yasuo</given-names></name><xref ref-type="aff" rid="a2"><sup>2</sup></xref></contrib><contrib id="cr4" contrib-type="author"><name><surname>Fukuoka</surname><given-names>Masahiro</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr5" contrib-type="author"><name><surname>Negoro</surname><given-names>Shunichi</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr6" contrib-type="author"><name><surname>Yana</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr7" contrib-type="author"><name><surname>Kusunoki</surname><given-names>Yoko</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr8" contrib-type="author"><name><surname>Kudoh</surname><given-names>Shinzoh</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr9" contrib-type="author"><name><surname>Kawase</surname><given-names>Ichiro</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr10" contrib-type="author"><name><surname>Kawahara</surname><given-names>Masaaki</given-names></name><xref ref-type="aff" rid="a3"><sup>3</sup></xref></contrib><contrib id="cr11" contrib-type="author"><name><surname>Ogawara</surname><given-names>Mitsumasa</given-names></name><xref ref-type="aff" rid="a3"><sup>3</sup></xref></contrib><contrib id="cr12" contrib-type="author"><name><surname>Kodama</surname><given-names>Nagahisa</given-names></name><xref ref-type="aff" rid="a3"><sup>3</sup></xref></contrib><contrib id="cr13" contrib-type="author"><name><surname>Kubota</surname><given-names>Kaoru</given-names></name><xref ref-type="aff" rid="a3"><sup>3</sup></xref></contrib><contrib id="cr14" contrib-type="author"><name><surname>Furuse</surname><given-names>Kiyoyuki</given-names></name><xref ref-type="aff" rid="a3"><sup>3</sup></xref></contrib></contrib-group><aff id="a1"><label><sup>1</sup></label>2nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital, 3&#x02010;7&#x02010;1 Habikino, Habikino, Osaka 583</aff><aff id="a2"><label><sup>2</sup></label>Scientific Affairs Department, Pharmaceuticals Group, Nippon Kayaku Co., Ltd., 11&#x02010;2, Fujimi 1&#x02010;chome, Chiyoda&#x02010;ku, Tokyo 102</aff><aff id="a3"><label><sup>3</sup></label>Department of Internal Medicine, National Kinki Central Hospital, 1180 Nagasone, Sakai, Osaka 591</aff><author-notes><corresp id="correspondenceTo"><label>*</label>To whom all correspondence should be addressed.</corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>1996</year></pub-date><volume>87</volume><issue>7</issue><issue-id pub-id-type="doi">10.1111/cas.1996.87.issue-7</issue-id><fpage>781</fpage><lpage>786</lpage><history>
Received March 15, 1996/Accepted May 2, 1996</history><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-87-781.pdf"/><abstract><p>Data on 16 potential risk factors for myelosuppression were assessed in 134 patients who received either vindesine and cisplatin (VP) or mitomycin C, vindesine and cisplatin (MVP) for inoperable stage III or IV non&#x02010;small cell lung cancer in a randomized trial. Determinant factors for myelosuppression were evaluated by using univariate analysis and the logistic regression model. Recursive partitioning and amalgamation (RPA) was also used to define patient subgroups frequently suffering from severe bone marrow toxicity. Overall, 33 (25%) of 134 patients experienced at least one episode of grade 4 leukopenia. In univariate analysis, age, body surface area, serum creatinine, and pretreatment hemoglobin concentration were associated with severe leukopenia. A multivariate analysis using the logistic regression method showed that only raised creatinine level was an independent predictor for grade 4 leukopenia (<italic>P</italic>=0.049). The RPA model generated three distinct subgroups based on age, body surface area and regimen. The three subgroups were distinguished by the frequency of severe (grade 4) leukopenia (50%, 25%, and 2.4%, respectively) (<italic>P</italic>&#x0003c;0.001). Grade 4 leukopenia occurred more frequently in patients in class 3 (age &#x02265;65 years and treatment with MVP). The RPA model was useful in identifying the risk factors for myelosuppression induced by cisplatin&#x02010;based chemotherapy, and in defining patient subgroups with elevated risk of toxicity.</p></abstract><kwd-group><kwd id="k1">Cisplatin&#x02010;based chemotherapy</kwd><kwd id="k2">Non&#x02010;small cell lung cancer</kwd><kwd id="k3">Bone marrow suppression</kwd><kwd id="k4">Elderly patient</kwd><kwd id="k5">Recursive partitioning and amalgamation</kwd></kwd-group><counts><ref-count count="19"/><page-count count="6"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 1996</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015</meta-value></custom-meta></custom-meta-group></article-meta></front><back><ref-list id="ss1"><title>REFERENCE</title><ref id="b1"><label>1</label><mixed-citation publication-type="journal" id="cit1"><string-name><surname>Gralla</surname>
,
<given-names>R. J.</given-names></string-name>
,
<string-name><surname>Casper</surname>
,
<given-names>E. S.</given-names></string-name>
,
<string-name><surname>Kelsen</surname>
,
<given-names>D. P.</given-names></string-name>
,
<string-name><surname>Braun</surname>
,
<given-names>D. W.</given-names></string-name>
,
<string-name><surname>Dukeman</surname>
,
<given-names>M. E.</given-names></string-name>
,
<string-name><surname>Martini</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Young</surname>
,
<given-names>C. W.</given-names></string-name>
and
<string-name><surname>Golbey</surname>
,
<given-names>R. B.</given-names></string-name><article-title>Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules</article-title>
.
<source>Ann. Intern. Med</source>
.,
<volume>95</volume>
,
<fpage>414</fpage>
&#x02013;
<lpage>420</lpage>
(
<year>1981</year>
).
<pub-id pub-id-type="pmid">7025719</pub-id></mixed-citation></ref><ref id="b2"><label>2</label><mixed-citation publication-type="journal" id="cit2"><string-name><surname>Kawahara</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Furuse</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Kodama</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Yamamoto</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Kubota</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Takada</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Negoro</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Kusunoki</surname>
,
<given-names>Y.</given-names></string-name>
,
<string-name><surname>Matsui</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Takifuji</surname>
,
<given-names>N.</given-names></string-name>
and
<string-name><surname>Fukuoka</surname>
,
<given-names>M.</given-names></string-name><article-title>A randomized study of cisplatin versus cisplatin plus vindesine for non&#x02010;small cell lung cancer</article-title>
.
<source>Cancer</source>
,
<volume>68</volume>
,
<fpage>714</fpage>
&#x02013;
<lpage>719</lpage>
(
<year>1991</year>
).
<pub-id pub-id-type="pmid">1649683</pub-id></mixed-citation></ref><ref id="b3"><label>3</label><mixed-citation publication-type="journal" id="cit3"><string-name><surname>Fukuoka</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Negoro</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Masuda</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Kusunoki</surname>
,
<given-names>Y.</given-names></string-name>
,
<string-name><surname>Matsui</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Ryu</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Takifuji</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Kudoh</surname>
,
<given-names>S.</given-names></string-name>
and
<string-name><surname>Takada</surname>
,
<given-names>M.</given-names></string-name><article-title>Mitomycin C, vindesine, and cisplatin in advanced non&#x02010;small&#x02010;cell lung cancer</article-title>
.
<source>Am. J. Clin. Oncol</source>
.,
<volume>15</volume>
,
<fpage>18</fpage>
&#x02013;
<lpage>22</lpage>
(
<year>1992</year>
).
<pub-id pub-id-type="pmid">1312768</pub-id></mixed-citation></ref><ref id="b4"><label>4</label><mixed-citation publication-type="journal" id="cit4"><string-name><surname>Burkes</surname>
,
<given-names>R. L.</given-names></string-name>
,
<string-name><surname>Ginsberg</surname>
,
<given-names>R. J.</given-names></string-name>
,
<string-name><surname>Shepherd</surname>
,
<given-names>F. A.</given-names></string-name>
,
<string-name><surname>Blackstein</surname>
,
<given-names>M. E.</given-names></string-name>
,
<string-name><surname>Goldberg</surname>
,
<given-names>M. E.</given-names></string-name>
,
<string-name><surname>Waters</surname>
,
<given-names>P. F.</given-names></string-name>
,
<string-name><surname>Patterson</surname>
,
<given-names>G. A.</given-names></string-name>
,
<string-name><surname>Todd</surname>
,
<given-names>T.</given-names></string-name>
,
<string-name><surname>Pearson</surname>
,
<given-names>F. G.</given-names></string-name>
,
<string-name><surname>Cooper</surname>
,
<given-names>J. D.</given-names></string-name><string-name><surname>Jones</surname>
,
<given-names>D.</given-names></string-name>
and
<string-name><surname>Lockwood</surname>
,
<given-names>G.</given-names></string-name><article-title>Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non&#x02010;small cell lung cancer; results of the Toronto phase II trial</article-title>
.
<source>J. Clin. Oncol</source>
.,
<volume>10</volume>
,
<fpage>580</fpage>
&#x02013;
<lpage>586</lpage>
(
<year>1992</year>
).
<pub-id pub-id-type="pmid">1312587</pub-id></mixed-citation></ref><ref id="b5"><label>5</label><mixed-citation publication-type="journal" id="cit5"><string-name><surname>Kris</surname>
,
<given-names>R. J.</given-names></string-name>
,
<string-name><surname>Gralla</surname>
,
<given-names>R. J.</given-names></string-name>
and
<string-name><surname>Wertheim</surname>
,
<given-names>M. S.</given-names></string-name><article-title>Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non&#x02010;small cell lung cancer</article-title>
.
<source>Cancer Treat. Rep</source>
.,
<volume>70</volume>
,
<fpage>1091</fpage>
&#x02013;
<lpage>1096</lpage>
(
<year>1986</year>
).
<pub-id pub-id-type="pmid">3527408</pub-id></mixed-citation></ref><ref id="b6"><label>6</label><mixed-citation publication-type="journal" id="cit6"><string-name><surname>Holmes</surname>
,
<given-names>E. C.</given-names></string-name>
and
<string-name><surname>Ruckdeschel</surname>
,
<given-names>J. C.</given-names></string-name><article-title>Preoperative chemotherapy for locally advanced non&#x02010;small cell lung cancer</article-title>
.
<source>Semin. Oncol</source>
.,
<volume>21</volume>
,
<fpage>97</fpage>
&#x02013;
<lpage>100</lpage>
(
<year>1994</year>
).
<pub-id pub-id-type="pmid">8052881</pub-id></mixed-citation></ref><ref id="b7"><label>7</label><mixed-citation publication-type="journal" id="cit7"><string-name><surname>Zagonel</surname>
,
<given-names>V.</given-names></string-name>
,
<string-name><surname>Tirelli</surname>
,
<given-names>U.</given-names></string-name>
,
<string-name><surname>Serraino</surname>
,
<given-names>D.</given-names></string-name>
,
<string-name><surname>Lo Re</surname>
,
<given-names>G.</given-names></string-name>
,
<string-name><surname>Merola</surname>
,
<given-names>M. C.</given-names></string-name>
,
<string-name><surname>Mascarin</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Trobo</surname>
,
<given-names>G. M.</given-names></string-name>
,
<string-name><surname>Carbone</surname>
,
<given-names>A.</given-names></string-name>
and
<string-name><surname>Monfardini</surname>
,
<given-names>S.</given-names></string-name><article-title>The aged patient with lung cancer</article-title>
.
<source>Drug Aging</source>
,
<volume>4</volume>
,
<fpage>34</fpage>
&#x02013;
<lpage>46</lpage>
(
<year>1994</year>
).
</mixed-citation></ref><ref id="b8"><label>8</label><mixed-citation publication-type="journal" id="cit8"><string-name><surname>Balducci</surname>
,
<given-names>L.</given-names></string-name>
,
<string-name><surname>Parker</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Sexton</surname>
,
<given-names>W.</given-names></string-name>
and
<string-name><surname>Tantranond</surname>
,
<given-names>P.</given-names></string-name><article-title>Pharmacology of antineoplastic agents in the elderly patient</article-title>
.
<source>Semin. Oncol</source>
.,
<volume>16</volume>
,
<fpage>76</fpage>
&#x02013;
<lpage>84</lpage>
(
<year>1989</year>
).
<pub-id pub-id-type="pmid">2645652</pub-id></mixed-citation></ref><ref id="b9"><label>9</label><mixed-citation publication-type="journal" id="cit9"><string-name><surname>Fukuoka</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Masuda</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Furuse</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Negoro</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Takada</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Matsui</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Takifuji</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Kudoh</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Kawahara</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Ogawara</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Kodama</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Kubota</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Yamamoto</surname>
,
<given-names>M.</given-names></string-name>
and
<string-name><surname>Kusunoki</surname>
,
<given-names>Y.</given-names></string-name><article-title>A randomized trial in inoperable non&#x02010;small&#x02010;cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin</article-title>
.
<source>J. Clin. Oncol</source>
.,
<volume>9</volume>
,
<fpage>606</fpage>
&#x02013;
<lpage>613</lpage>
(
<year>1991</year>
).
<pub-id pub-id-type="pmid">1648597</pub-id></mixed-citation></ref><ref id="b10"><label>10</label><mixed-citation publication-type="book" id="cit10"><collab collab-type="authors">World Health Organization.</collab>
&#x0201c;
<chapter-title>WHO Handbook for Reporting Results of Cancer Treatment</chapter-title>
,&#x0201d;
<source>WHO Offset Publication No. 48</source>
.
World Health Organization
(
<year>1979</year>
),
<publisher-name>World Health Organization</publisher-name>
,
Geneva
,
Switzerland
.
</mixed-citation></ref><ref id="b11"><label>11</label><mixed-citation publication-type="journal" id="cit11"><string-name><surname>Cox</surname>
,
<given-names>D. R.</given-names></string-name><article-title>Regression model and life tables</article-title>
.
<source>J. R. Stat. Soc</source>
.,
<volume>34</volume>
,
<fpage>187</fpage>
&#x02013;
<lpage>220</lpage>
(
<year>1972</year>
).
</mixed-citation></ref><ref id="b12"><label>12</label><mixed-citation publication-type="book" id="cit12"><string-name><surname>Ciampi</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Chang</surname>
,
<given-names>C.&#x02010;H.</given-names></string-name>
,
<string-name><surname>Hogg</surname>
,
<given-names>S.</given-names></string-name>
and
<string-name><surname>McKinney</surname>
,
<given-names>S.</given-names></string-name><chapter-title>Recursive partition; a versatile method for exploratory data analysis in biostatics</chapter-title>
.
In
<source>&#x0201c;Biostatistics</source>
,&#x0201d;
ed.
<person-group person-group-type="editor"><name><surname>MacNeill</surname><given-names>I. B.</given-names></name></person-group>
and
<person-group person-group-type="editor"><name><surname>Umphery</surname><given-names>G. J.</given-names></name></person-group>
,
pp.
<fpage>23</fpage>
&#x02013;
<lpage>50</lpage>
(
<year>1987</year>
).
<publisher-name>D. Reidel Publishing Company</publisher-name>
,
Dordrecht
.
</mixed-citation></ref><ref id="b13"><label>13</label><mixed-citation publication-type="book" id="cit13"><string-name><surname>Dennis</surname>
,
<given-names>V. W.</given-names></string-name><chapter-title>Investigations of renal function</chapter-title>
.
In
<source>&#x0201c;Cecil Textbook of Medicine</source>
,&#x0201d;
ed.
<person-group person-group-type="editor"><name><surname>Wyngaarden</surname><given-names>J. B.</given-names></name></person-group>
and
<person-group person-group-type="editor"><name><surname>Smith</surname><given-names>L. H.</given-names><suffix>Jr.</suffix></name></person-group>
,
pp.
<fpage>520</fpage>
&#x02013;
<lpage>528</lpage>
(
<year>1988</year>
).
<publisher-name>W.B. Saunders Company</publisher-name>
,
Philadelphia
.
</mixed-citation></ref><ref id="b14"><label>14</label><mixed-citation publication-type="journal" id="cit14"><string-name><surname>Solomon</surname>
,
<given-names>D.</given-names></string-name>
,
<string-name><surname>Brown</surname>
,
<given-names>A. S.</given-names></string-name>
,
<string-name><surname>Brummel&#x02010;Smith</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Burgess</surname>
,
<given-names>L.</given-names></string-name>
,
<string-name><surname>D'Agostino</surname>
,
<given-names>R. B.</given-names></string-name>
,
<string-name><surname>Goldschmidt</surname>
,
<given-names>J. W.</given-names></string-name>
,
<string-name><surname>Halter</surname>
,
<given-names>J. B.</given-names></string-name>
,
<string-name><surname>Hazzard</surname>
,
<given-names>W. R.</given-names></string-name>
,
<string-name><surname>Jahnigen</surname>
,
<given-names>D. W.</given-names></string-name>
,
<string-name><surname>Phelps</surname>
,
<given-names>C.</given-names></string-name>
,
<string-name><surname>Raskind</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Schrier</surname>
,
<given-names>R. W.</given-names></string-name>
,
<string-name><surname>Sox</surname>
,
<suffix>Jr.</suffix>
,
<given-names>H. C.</given-names></string-name>
,
<string-name><surname>Williams</surname>
,
<given-names>S. V.</given-names></string-name>
and
<string-name><surname>Wykle</surname>
,
<given-names>M.</given-names></string-name><article-title>National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision&#x02010;making</article-title>
.
<source>J. Am. Geriatr. Soc</source>
.,
<volume>36</volume>
,
<fpage>342</fpage>
&#x02013;
<lpage>347</lpage>
(
<year>1988</year>
).
<pub-id pub-id-type="pmid">3280648</pub-id></mixed-citation></ref><ref id="b15"><label>15</label><mixed-citation publication-type="journal" id="cit15"><string-name><surname>Chatta</surname>
,
<given-names>G. S.</given-names></string-name>
,
<string-name><surname>Price</surname>
,
<given-names>T. H.</given-names></string-name>
,
<string-name><surname>Stratton</surname>
,
<given-names>J. R.</given-names></string-name>
and
<string-name><surname>Dale</surname>
,
<given-names>D. C.</given-names></string-name><article-title>Aging and marrow neutrophil reserves</article-title>
.
<source>J. Am. Geriatr. Soc</source>
.,
<volume>42</volume>
,
<fpage>77</fpage>
&#x02013;
<lpage>81</lpage>
(
<year>1994</year>
).
<pub-id pub-id-type="pmid">7506277</pub-id></mixed-citation></ref><ref id="b16"><label>16</label><mixed-citation publication-type="journal" id="cit16"><string-name><surname>Hoagland</surname>
,
<given-names>H.</given-names></string-name><article-title>Hematologic complications of cancer chemotherapy</article-title>
.
<source>Semin. Oncol</source>
.,
<volume>9</volume>
,
<fpage>95</fpage>
&#x02013;
<lpage>102</lpage>
(
<year>1982</year>
).
<pub-id pub-id-type="pmid">7071611</pub-id></mixed-citation></ref><ref id="b17"><label>17</label><mixed-citation publication-type="journal" id="cit17"><string-name><surname>Ettinger</surname>
,
<given-names>D.</given-names></string-name><article-title>Metastatic non&#x02010;small cell lung cancer</article-title>
.
<source>Lung Cancer</source>
,
<volume>9</volume>
(
<issue>Suppl.</issue>
),
<fpage>S69</fpage>
&#x02013;
<lpage>S79</lpage>
(
<year>1993</year>
).
</mixed-citation></ref><ref id="b18"><label>18</label><mixed-citation publication-type="journal" id="cit18"><string-name><surname>Miller</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Herndon</surname>
,
<given-names>II J.</given-names></string-name>
,
<string-name><surname>Hollis</surname>
,
<given-names>D.</given-names></string-name>
,
<string-name><surname>Ellerton</surname>
,
<given-names>J.</given-names></string-name>
,
<string-name><surname>Langleben</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Richards</surname>
,
<given-names>IIF.</given-names></string-name>
and
<string-name><surname>Green</surname>
,
<given-names>M.</given-names></string-name><article-title>Schedule dependency of 21&#x02010;day oral versus 3&#x02010;day intravenous etoposide in combination with intravenous cisplatin in extensive&#x02010;stage small&#x02010;cell lung cancer: a randomized phase III study of the cancer and leukemia Group B</article-title>
.
<source>J. Clin. Oncol</source>
.,
<volume>13</volume>
,
<fpage>1871</fpage>
&#x02013;
<lpage>1879</lpage>
(
<year>1995</year>
).
<pub-id pub-id-type="pmid">7636529</pub-id></mixed-citation></ref><ref id="b19"><label>19</label><mixed-citation publication-type="journal" id="cit19"><collab collab-type="authors">The American Society of Clinical Oncology.</collab><article-title>American Society of Clinical Oncology recommendations for the use of hematopoietic colony&#x02010;stimulating factors: evidence&#x02010;based, clinical practice guidelines</article-title>
.
<source>J. Clin. Oncol</source>
.,
<volume>12</volume>
,
<fpage>2471</fpage>
&#x02013;
<lpage>2508</lpage>
(
<year>1994</year>
).
<pub-id pub-id-type="pmid">7964965</pub-id></mixed-citation></ref></ref-list></back></article>